As with some other NaV1.5 mutants, E1784K is associated with both a gain-of-function disorder (LQT3) and a loss-of-function disorder (BrS1) [22,57]; pharmacological interventions for these mixed syndrome mutants may prove difficult [58]. Here, SCN5A is linked to long QT syndrome 3.